Fig. 1 · Structure

Documents & Downloads

HBX 41108

Cat. No. A13352 CAS 924296-39-9

USP 7 inhibitor

HBX 41108 is an inhibitor of ubiquitin-specific protease (USP) 7 activity (IC50 = 424 nM).

In Stock

Publications for HBX 41108

1 publication citing this product

  1. Kevin Bohm, .et al. , Arch Pharm (Weinheim), 2023, Jul;356(7):e2200661 PMID: 37196427

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

HBX 41108 inhibits USP7 but has broad DUB activity. In a MALDI-TOF panel, 5 μM inhibited 25 of 32 DUBs by more than 70%; separate concentration-response experiments showed stronger inhibition of USP8 than USP7. Cellular effects therefore require caution when attributed specifically to USP7. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

In AGE-exposed HUVECs, HBX 41108 pretreatment partly restored the CCK-8 signal and reduced G0/G1 accumulation, senescence staining and p53/p21 protein abundance. These are model-specific pharmacological observations; parallel USP7 knockdown does not establish compound selectivity. [2]

Broad DUB inhibition in a 32-enzyme panel

Biochemical assay · 32 recombinant human DUBs with their preferred diubiquitin substrates [1]

HBX 41,108 inhibited a broad panel of DUBs rather than showing USP7-specific inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DUBs inhibited by more than 70% at 5 μMpanel inhibition 25 of 32 DUBs; >70% inhibition at 5 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 and 5 μM
Exposure duration
35 min preincubation, then 60 min substrate incubation at 30°C
Method
Cell-free inhibitor panel; enzyme-specific diubiquitin substrates.
Reported limits
Vehicle identity and concentration not specified in the retrieved main text; SI acquired but not read.
Methods and source locations

Compound reported in the paper: HBX 41108; Compound label in the paper: HBX 41,108

Applies to the named research compound under the reported conditions; no tested Adooq lot, salt conversion, or human efficacy inference.

Figure 3 and caption; Methods: Materials; In vitro DUB assays and inhibitor screening

DUBs inhibited by more than 70% at 5 μM: MALDI-TOF quantitation of monoubiquitin released from diubiquitin; duplicate independent experiments. — Results: Assessing potency and selectivity of DUB inhibitors; Figure 3 and caption

USP7 and USP8 concentration-response comparison

Biochemical assay · Recombinant full-length human USP7 (His-tagged) with K11-linked diubiquitin; full-length human USP8 (His-tagged) with K63-linked diubiquitin [1]

In this assay, HBX 41,108 inhibited USP8 more potently than USP7. This limits attribution of cellular effects to USP7 alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
USP7-mediated K11-linked diubiquitin hydrolysisIC50 5.97 ± 3.19 μM[1]
USP8-mediated K63-linked diubiquitin hydrolysisIC50 0.21 ± 0.04 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
35 min preincubation, then 60 min substrate incubation at 30°C
Method
Cell-free concentration-response assays; no-inhibitor conditions included.
Reported limits
Exact per-enzyme concentration series and compound vehicle are not transcribed from SI; no concentrations inferred from curves.
Methods and source locations

Compound reported in the paper: HBX 41108; Compound label in the paper: HBX 41,108

Applies to the named research compound under the reported conditions; no tested Adooq lot, salt conversion, or human efficacy inference.

Figure 4 and caption; Table 1 (construct descriptors only); Methods: In vitro DUB assays and inhibitor screening

USP7-mediated K11-linked diubiquitin hydrolysis: MALDI-TOF; four-parameter logistic fitting. Figure 4 reports three different experiments and SD error bars; the meaning of ± on fitted IC50 annotations is not separately defined. — Figure 4, HBX 41,108 column, middle panel; caption; Results: Assessing potency and selectivity

USP8-mediated K63-linked diubiquitin hydrolysis: Same assay family and fitting approach; substrate differs from USP7. Figure 4 reports three different experiments and SD error bars; fitted-IC50 ± semantics are not separately defined. — Figure 4, HBX 41,108 column, top panel and caption

Endothelial-cell responses to HBX 41108 under AGE exposure

Cell-based study · Human umbilical vein endothelial cells (HUVECs), exposed to advanced glycation end products (AGEs) [2]

HBX 41108 partly reversed AGE-associated loss of CCK-8 signal, G0/G1 accumulation and senescence staining, and lowered p53/p21 protein signals relative to AGE-exposed vehicle-labelled controls. A parallel USP7-knockdown arm supported pathway involvement but does not establish drug selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCK-8 signal, cell-cycle distribution and senescence-associated β-galactosidase stainingdirection of response Increased CCK-8 signal; reduced G0/G1 accumulation and senescence staining versus AGEs+shNC+vehicle[2]
p53 and p21 protein abundancedirection of response Reduced p53 and p21 versus AGEs+shNC+vehicle[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM HBX 41108; subsequent AGEs 250 μg/mL
Exposure duration
HBX 41108 for 24 h before AGEs for 24 h; CCK-8 readouts at 0, 12, 24 and 48 h after plating treated cells
Method
Pharmacological pretreatment followed by AGE exposure; parallel genetic comparator was a separate arm, not a drug combination.
Reported limits
Vehicle composition and whether HBX remained present throughout AGE exposure are not specified. Replicate type beyond global triplicate statement is not defined.
Methods and source locations

Compound reported in the paper: HBX 41108; Compound label in the paper: HBX 41108

Applies to the named research compound under the reported conditions; no tested Adooq lot, salt conversion, or human efficacy inference.

Figure 2C–H; Methods: Experimental grouping; CCK-8 assay; Flow cytometry of cell cycle; Senescence β-galactosidase staining; Western blot analysis; Statistical analysis

CCK-8 signal, cell-cycle distribution and senescence-associated β-galactosidase staining: CCK-8, flow cytometry and SA-β-Gal staining; global statistics: experiments in triplicate, mean±SD. Exact effect sizes not extracted from graphs. — Figure 2C–F and caption; Results: Inhibiting USP7 expression and its deubiquitinating activity

p53 and p21 protein abundance: Immunoblotting with GAPDH loading control and quantification; no exact bar heights inferred. — Figure 2G,H and caption

In Vivo Studies

In diabetic rats with dorsal skin wounds, HBX 41108 treatment increased wound-healing measures and reduced blood glucose at day 14 compared with diabetic vehicle-labelled controls. These preclinical observations do not establish human efficacy or a USP7-specific mechanism. [2]

Wound healing in diabetic rats

Animal study · STZ-induced diabetic male Sprague–Dawley rats with dorsal skin wounds [2]

HBX 41108 improved wound-healing measures in this diabetic-rat model. No human treatment benefit or USP7-specific mechanism is established by this experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Wound healing and tissue morphologydirection of response Higher wound-healing rate at days 7 and 14 versus STZ+vehicle; newly formed epithelium described at day 7[2]
Blood glucosedirection of response Decreased at day 14 versus STZ+vehicle[2]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Once daily
Treatment course
14 consecutive days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Diabetic rats treated with HBX 41108
100 mg/kg/day
STZ+vehicle group; nondiabetic saline-treated control groupHigher wound-healing rate at days 7 and 14 and lower blood glucose at day 14 versus diabetic vehicle-labelled controls; qualitative epithelial formation at day 7.[2]
Diabetic rats treated with HBX 41108
Model: Male Sprague–Dawley rats, 4–6 weeks, 180–200 g; STZ-induced diabetes with dorsal skin wounds; 36 rats randomized across three groups
Reported limits: HBX vehicle identity, per-timepoint/per-assay n, blinding, exposure and safety endpoints are not specified in the retrieved article. Total group allocation does not establish n for every endpoint.
Methods and source locations

Compound reported in the paper: HBX 41108; Compound label in the paper: HBX 41108

Applies to the named research compound under the reported conditions; no tested Adooq lot, salt conversion, or human efficacy inference.

Methods: Animal models; Statistical analysis; Figure 5A–D and caption; Results: HBX 41108 facilitates wound healing in diabetic rats

Wound healing and tissue morphology: Wound photographs, wound-healing rate and H&E staining. No numerical rates inferred from plotted points. — Figure 5B–D and caption; Results: HBX 41108 facilitates wound healing in diabetic rats

Blood glucose: Blood glucose measurements on days 0, 7 and 14; exact concentrations not inferred from bars. — Figure 5A and caption; Results: HBX 41108 facilitates wound healing in diabetic rats

Diabetic rats treated with HBX 41108 · Methods: Animal models; Figure 5A–D and caption; Results: HBX 41108 facilitates wound healing in diabetic rats

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 924296-39-9
Applications USP 7 inhibitor
Formula C13H3ClN4O
Molecular Weight 266.64
SMILES
C1=CC2=C(C=C1Cl)C(=O)C3=NC(=C(N=C23)C#N)C#N

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Maria Stella Ritorto, Richard Ewan, Ana B Perez-Oliva, et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry Nature Communications (2014). PMID: 25159004 DOI: 10.1038/ncomms5763 Source material
  2. [2] Xu Li, Tao Wang, Yue Tao, et al. Inhibition of USP7 suppresses advanced glycation end-induced cell cycle arrest and senescence of human umbilical vein endothelial cells through ubiquitination of p53 Acta Biochimica et Biophysica Sinica (2022). PMID: 35538032 DOI: 10.3724/abbs.2022003 Source material

Publications

1 publication citing this product

  1. Kevin Bohm, .et al. , Arch Pharm (Weinheim), 2023, Jul;356(7):e2200661 PMID: 37196427

Added to your cart

View Cart Checkout
Loading...